Stifel analyst Rick Wise lowered the firm’s price target on OrthoPediatrics (KIDS) to $20 from $32 and keeps a Buy rating on the shares after the company pre-announced below-consensus Q3 sales and lowered 2025 guidance by more than the shortfall. The negative Q3 surprise “clearly is disappointing,” but the factors driving the miss appear to be outside of managements’ control, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics price target lowered to $22 from $30 at Piper Sandler
- OrthoPediatrics: Strong Growth Prospects and Acquisition Potential Justify Buy Rating
- Closing Bell Movers: Levi Strauss down 8% after results
- OrthoPediatrics reports preliminary Q3 revenue $61.2M, consensus $63.63M
- OrthoPediatrics cuts FY25 revenue view to $233.5M-$234.5M from $237M-$242M